Hamid Deliri, MD
Cardiovascular Disease · Wilmington, DENPI 1801834833
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 72.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $2,718 and has fallen 74.5% since, to $693 in 2025.
Across 166 payments — averaging $59.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$771
- ZOLL Respicardia, Inc.$442
- Boston Scientific$350
- Impulse Dynamics (USA) Inc.$348
- Biosense Webster, Inc.$260
- plus $617 from 8 others
What the payments were for
- Consulting fees$1,76018%
- Travel & lodging$3,20632%
- Food & beverage$4,99050%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 103 | $7,168 |
| Medtronic(2 entities) | 20 | $771 |
| ZOLL Respicardia, Inc. | 4 | $442 |
| Boston Scientific | 12 | $350 |
| Impulse Dynamics (USA) Inc. | 4 | $348 |
| Biosense Webster, Inc. | 2 | $260 |
| Sanofi-aventis U.S. LLC | 2 | $230 |
| Johnson & Johnson | 8 | $194 |
| Novartis | 3 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $44 |
| Inari Medical, Inc. | 1 | $30 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$3,115
- Anthem CRT Pacemaker$1,760
- Carto 3$615
- remede System$313
- OPTIMIZER$246
- Micra$161
- Fortify Assura, Ellipse ICD$157
- OPTIMIZER SMART SYSTEM$141
- Soundstar$118
- AURORA EV-ICD MRI SURESCAN$102
- XARELTO$100
How this compares
$9,956 in reported general payments places this provider in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $200,940 |
| XareltoRivaroxaban | 90 | $92,442 |
| EntrestoSacubitril/Valsartan | 45 | $55,433 |
| JardianceEmpagliflozin | 15 | $19,652 |
| MultaqDronedarone Hcl | 12 | $14,791 |
| CorlanorIvabradine Hcl | 13 | $8,404 |
| Rosuvastatin Calcium | 195 | $3,904 |
| Metoprolol Succinate | 155 | $2,064 |
| Bumetanide | 25 | $2,051 |
| Atorvastatin Calcium | 106 | $1,710 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 71 | $1,579 |
| Carvedilol | 102 | $1,145 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $903 |
| Pravastatin Sodium | 47 | $784 |
| Ezetimibe | 23 | $734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $200,940147 claims |
| Johnson & JohnsonXarelto | $194 | $92,44290 claims |
| NovartisEntresto | $56 | $55,43345 claims |
| Sanofi-aventis U.S. LLCMultaq | $230 | $14,79112 claims |
| AmgenCorlanor | $16 | $8,40413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Wilmington
- Vinay HosmaneWilmington$256K
- Piamsook AngkeowWilmington$4K
- Andra PopescuWilmington$3K
- Yolanda HendleyWilmington$3K
- Vincent MarmoWilmington$2K
- George DavisWilmington$2K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.